Abstract |
Amphotericin B (AmB), is a highly effective antileishmanial agent used as first-line treatment in different formulations in visceral leishmaniasis endemic areas of Bihar, India. However, parenteral infusion, prolonged hospitalization, and toxicity are major hurdles. Our previous work demonstrated the efficacy and stability of functionalized carbon nanotubes as a delivery mechanism for AmB. In this study, using the hamster model, we have shown that this novel formulation of AmB can be administered orally, resulting in 99% inhibition of parasite growth following a 5-day course at 15 mg/kg body weight.
|
Authors | Vijay Kumar Prajapati, Kalpna Awasthi, Thakur Prasad Yadav, Madhukar Rai, Onkar Nath Srivastava, Shyam Sundar |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 205
Issue 2
Pg. 333-6
(Jan 15 2012)
ISSN: 1537-6613 [Electronic] United States |
PMID | 22158723
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiprotozoal Agents
- Drug Carriers
- Nanotubes, Carbon
- Amphotericin B
|
Topics |
- Administration, Oral
- Amphotericin B
(administration & dosage, therapeutic use)
- Animals
- Antiprotozoal Agents
(administration & dosage, therapeutic use)
- Chemistry, Pharmaceutical
- Cricetinae
- Drug Carriers
- Leishmania donovani
- Leishmaniasis, Visceral
(drug therapy, parasitology)
- Male
- Nanotubes, Carbon
- Parasite Load
- Splenic Diseases
(drug therapy, parasitology)
|